MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$79,626K
EPS
-$3,650
Unit: Thousand (K) dollars

Income Statement
2026-03-31
Research and development
70,873
General and administrative
13,787
Total operating expenses
84,660
Loss from operations
-84,660
Interest income
5,716
Other income, net
79
Total other income
5,795
Net loss
-78,865
Unrealized loss
-761
Comprehensive loss
-79,626
Basic EPS
-3,650
Diluted EPS
-3,650
Basic Average Shares
21,607
Diluted Average Shares
21,607
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Comprehensive loss-$79,626K Interest income$5,716K Other income, net$79K Net loss-$78,865K Unrealized loss-$761K Total other income$5,795K Loss from operations-$84,660K Total operatingexpenses$84,660K Research and development$70,873K General andadministrative$13,787K

Kailera Therapeutics, Inc. (KLRA)

Kailera Therapeutics, Inc. (KLRA)